Atherosclerosis Cardiovascular Disease study: Orforglipron
Official title A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
ClinicalTrials.gov ID: NCT07241390
What this study is testing
What is Orforglipron?
An investigational oral medication being studied for atherosclerotic cardiovascular disease and chronic kidney disease.
Also referred to as LY3502970.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study will compare cardiovascular outcomes in people with atherosclerotic cardiovascular disease and/or chronic kidney disease who receive Orforglipron or a placebo.
- Who it's for
- Adults who have atherosclerotic cardiovascular disease or chronic kidney disease.
- What's involved
- Participants will take either Orforglipron or a placebo and attend scheduled visits for health checks and tests.
- Time commitment
- The study lasts about 5 years with regular clinic visits as scheduled.
- Phase 3: a large, late-stage study
- You might receive a placebo (an inactive treatment) instead of the study drug.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 50 and older
You may be able to join if
- Have established ASCVD and/or CKD
You likely can't join if
- Have type 1 diabetes
- Have had a major heart condition within 60 days prior to screening
- Have New York Heart Association Functional Classification Class IV heart failure
The study team makes the final eligibility decision.
Where it is enrolling
- Bahía Blanca, Argentina
- Buenos Aires, Argentina
- C.a.b.a., Argentina
- CABA, Argentina
- Corrientes, Argentina
- Córdoba, Argentina
- Esperanza, Argentina
- Godoy Cruz, Argentina
- Granadero Baigorria, Argentina
- Junín, Argentina
- Lanus, Argentina
- Mar del Plata, Argentina
- Mendoza, Argentina
- Quilmes, Argentina
- Ramos Mejía, Argentina
- Río Cuarto, Argentina
- Rosario, Argentina
- S3000epv, Argentina
- San Isidro, Argentina
- SAN M. de Tucuman, Argentina
+ 357 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 50 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Bahía Blanca, Argentina; Buenos Aires, Argentina; C.a.b.a., Argentina; CABA, Argentina; Corrientes, Argentina; Córdoba, Argentina and 371 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.